Asset Management One Co. Ltd. Buys 4,795 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Asset Management One Co. Ltd. increased its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 7.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,149 shares of the company’s stock after acquiring an additional 4,795 shares during the period. Asset Management One Co. Ltd.’s holdings in Inari Medical were worth $3,504,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Legato Capital Management LLC bought a new stake in Inari Medical during the fourth quarter worth about $681,000. Jennison Associates LLC raised its holdings in Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after acquiring an additional 186,617 shares in the last quarter. R Squared Ltd bought a new stake in Inari Medical during the fourth quarter worth about $45,000. KBC Group NV raised its holdings in Inari Medical by 31.5% during the fourth quarter. KBC Group NV now owns 2,333 shares of the company’s stock worth $119,000 after acquiring an additional 559 shares in the last quarter. Finally, AMI Asset Management Corp bought a new stake in Inari Medical in the fourth quarter valued at approximately $1,651,000. Institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on NARI. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Piper Sandler upped their price objective on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research note on Tuesday, January 7th. Oppenheimer began coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective on the stock. Canaccord Genuity Group restated a “hold” rating and issued a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Truist Financial upped their price objective on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $68.00.

Insider Buying and Selling

In related news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William Hoffman sold 200,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the sale, the director now directly owns 238,987 shares in the company, valued at $14,451,543.89. This represents a 45.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 263,000 shares of company stock valued at $15,599,470 over the last 90 days. 10.60% of the stock is owned by corporate insiders.

Inari Medical Trading Up 0.1 %

Inari Medical stock opened at $79.97 on Thursday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99. The stock’s 50 day moving average is $70.53 and its 200-day moving average is $55.01. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.